Neoleukin Therapeutics Inc. (NASDAQ:NLTX) went up by 13.61% from its latest closing price compared to the recent 1-year high of $10.56. The company’s stock price has collected 13.92% of gains in the last five trading sessions.
Is It Worth Investing in Neoleukin Therapeutics Inc. (NASDAQ :NLTX) Right Now?
Plus, the 36-month beta value for NLTX is at 1.18. Opinions of the stock are interesting as 7 analysts out of 7 who provided ratings for Neoleukin Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $14.57, which is $13.46 above the current price. NLTX currently public float of 33.37M and currently shorts hold a 6.71% ratio of that float. Today, the average trading volume of NLTX was 316.50K shares.
NLTX’s Market Performance
NLTX stocks went up by 13.92% for the week, with a monthly jump of 6.73% and a quarterly performance of -37.64%, while its annual performance rate touched -88.88%. The volatility ratio for the week stands at 9.14% while the volatility levels for the past 30 days are set at 9.76% for Neoleukin Therapeutics Inc. The simple moving average for the period of the last 20 days is 12.15% for NLTX stocks with a simple moving average of -71.44% for the last 200 days.
Analysts’ Opinion of NLTX
Many brokerage firms have already submitted their reports for NLTX stocks, with Piper Sandler repeating the rating for NLTX by listing it as a “Overweight.” The predicted price for NLTX in the upcoming period, according to Piper Sandler is $30 based on the research report published on August 06th of the previous year 2021.
Stifel, on the other hand, stated in their research note that they expect to see NLTX reach a price target of $18. The rating they have provided for NLTX stocks is “Buy” according to the report published on January 06th, 2021.
Robert W. Baird gave a rating of “Outperform” to NLTX, setting the target price at $25 in the report published on September 23rd of the previous year.
NLTX Trading at -3.56% from the 50-Day Moving Average
After a stumble in the market that brought NLTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.49% of loss for the given period.
Volatility was left at 9.76%, however, over the last 30 days, the volatility rate increased by 9.14%, as shares surge +18.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.90% lower at present.
During the last 5 trading sessions, NLTX rose by +13.92%, which changed the moving average for the period of 200-days by -85.38% in comparison to the 20-day moving average, which settled at $0.9983. In addition, Neoleukin Therapeutics Inc. saw -76.97% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NLTX starting from Patel Priti, who sale 5,538 shares at the price of $1.22 back on May 02. After this action, Patel Priti now owns 6,462 shares of Neoleukin Therapeutics Inc., valued at $6,749 using the latest closing price.
DRACHMAN JONATHAN G, the President and CEO of Neoleukin Therapeutics Inc., purchase 50,000 shares at $6.45 during a trade that took place back on Aug 25, which means that DRACHMAN JONATHAN G is holding 25,000 shares at $322,450 based on the most recent closing price.
Stock Fundamentals for NLTX
Equity return is now at value -41.10, with -36.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 16.67.